SELECTA BIOSCI. DL -,0001
SELECTA BIOSCI. DL -,0001
Aktie · US8162121045 · SELB · A2AML0 (LSSI)
Übersicht Finanzkennzahlen
Kein Kurs
n/a

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
- - - - -1,87 % 0,32 % -80,72 %

Firmenprofil zu SELECTA BIOSCI. DL -,0001 Aktie

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Investierte Fonds

Folgende Fonds haben in investiert: SELECTA BIOSCI. DL -,0001 investiert:

Fonds
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in Mio
15,70
Anteil (%)
0,04 %

Unternehmensdaten

Name SELECTA BIOSCI. DL -,0001
Firma Selecta Biosciences, Inc.
Symbol SELB
Website https://selectabio.com
Heimatbörse LSSI Lang & Schwarz
WKN A2AML0
ISIN US8162121045
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Carsten Brunn Ph.D.
Marktkapitalisierung 135 Mio
Land Vereinigte Staaten von Amerika
Währung EUR
Mitarbeiter 0,1 T
Adresse 65 Grove Street, 02472 Watertown
IPO Datum 2016-06-22

Ticker Symbole

Name Symbol
NASDAQ SELB

Weitere Aktien

Investoren die SELECTA BIOSCI. DL -,0001 die halten, haben auch folgende Aktien im Depot:
ALPHABET INC - CLASS A
ALPHABET INC - CLASS A Aktie
AMGEN INC
AMGEN INC Aktie
AUTODESK INC
AUTODESK INC Aktie
CINTAS CORP
CINTAS CORP Aktie
CISCO SYSTEMS INC
CISCO SYSTEMS INC Aktie
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Aktie
INTEL CORP
INTEL CORP Aktie
KENADYR METALS CORP
KENADYR METALS CORP Aktie
MICROSOFT CORP
MICROSOFT CORP Aktie
PORTLAND GEN.ELEC.CO
PORTLAND GEN.ELEC.CO Aktie
PROCTER GAMBLE CORP
PROCTER GAMBLE CORP Aktie
REDHILL BIOPHARMA LTDICAN DEPOSITARY SHARES
REDHILL BIOPHARMA LTDICAN DEPOSITARY SHARES Hinterlegungsschein
Vanguard FTSE 100 Index Unit Trust GBP Acc
Vanguard FTSE 100 Index Unit Trust GBP Acc Fonds
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Aktie
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025